| Literature DB >> 35871218 |
Qi Wu1, Zhi-Jie Gao2, Xin Yu2, Ping Wang3.
Abstract
Nutriments have been deemed to impact all physiopathologic processes. Recent evidences in molecular medicine and clinical trials have demonstrated that adequate nutrition treatments are the golden criterion for extending healthspan and delaying ageing in various species such as yeast, drosophila, rodent, primate and human. It emerges to develop the precision-nutrition therapeutics to slow age-related biological processes and treat diverse diseases. However, the nutritive advantages frequently diversify among individuals as well as organs and tissues, which brings challenges in this field. In this review, we summarize the different forms of dietary interventions extensively prescribed for healthspan improvement and disease treatment in pre-clinical or clinical. We discuss the nutrient-mediated mechanisms including metabolic regulators, nutritive metabolism pathways, epigenetic mechanisms and circadian clocks. Comparably, we describe diet-responsive effectors by which dietary interventions influence the endocrinic, immunological, microbial and neural states responsible for improving health and preventing multiple diseases in humans. Furthermore, we expatiate diverse patterns of dietotheroapies, including different fasting, calorie-restricted diet, ketogenic diet, high-fibre diet, plants-based diet, protein restriction diet or diet with specific reduction in amino acids or microelements, potentially affecting the health and morbid states. Altogether, we emphasize the profound nutritional therapy, and highlight the crosstalk among explored mechanisms and critical factors to develop individualized therapeutic approaches and predictors.Entities:
Mesh:
Year: 2022 PMID: 35871218 PMCID: PMC9308782 DOI: 10.1038/s41392-022-01104-w
Source DB: PubMed Journal: Signal Transduct Target Ther ISSN: 2059-3635
Fig. 1Research history of dietary regulation. The advances in dietary regulation can be roughly divided into three stages. Stage I, dietary regulation discovery and initial characterizations of their effects on body function, including dietary interventions based on traditional eating habits, such as fasting,[367] caloric restriction,[368] high-fibre diet,[369] fermented/probiotic diet,[370] Mediterranean diet[371] and protein restriction,[372] some new dietary interventions, such as ketogenic diet,[373] glucose and carbohydrate restriction,[374] amino acid intervention[375] and micronutrient intervention.[376,377] Stage II, key molecular mechanisms of dietary interventions were identified, including mTORC1,[378] AMPK,[379] FOXOs[380] and Sirtuins and NAD.[381] To date, whether and how metabolic interventions interfere with these signalling pathways to function has been extensively studied. Stage III, dietary interventions have been being explored for their impact on the overall metabolic network of the body to develop precision-nutrition therapeutics
Types of dietary interventions
| Dietary intervention | Description | |
|---|---|---|
| Fasting | Classical | Starvation for random 2 days. |
| Prolonged | Starvation for random >2 days. | |
| Intermittent | The alternate pattern of ad libitum food intake-encompassing regimes that may include alternate-day fasting (ADF), modified ADF (limited calories supplied during fasting day), or 5:2 diet (days of caloric restriction per week). | |
| Time-restricted | The time-limited fasting during a period of several hours per day. | |
| Caloric restriction | Classical | Reduced caloric intake (20–30% below average) without undergoing malnutrition during the entire period of dietary intervention. |
| Fasting-mimicking | Four days of diet that mimics fasting (FMD) consisting of very low calorie/low protein. The ad libitum diet is fed between the period of FMD cycles. | |
| Time-restricted | The time-limited consumption of calories during a period of several hours per day | |
| Ketogenic diet | High-fat, moderate-protein and low-carbohydrate (usually <40 g/day) diets. The fat ingredients including saturated fatty acid (SFA), monounsaturated fatty acid (MUFA) and polyunsaturated fatty acids (PUFA) vary in different studies. | |
| Glucose and carbohydrate restriction | Carbohydrate consumption is restricted relative to the average diet and is replaced by food containing a higher percentage of fat and protein. Glucose restriction refers to specific restriction of glucose intake instead of other forms of complex carbohydrates and sweeteners. | |
| High-fibre diet/short chain fatty acids (SCFAs) supplements | Soluble dietary fibre (20 g/day) mainly by intake of fruits, vegetables, legumes and whole grain to produce SCFAs. | |
| Fermented/probiotic diet | Commercial prebiotics, yogurt, matured cheese. | |
| Plants-based diets/Mediterranean diet | Food mainly consists of fruits, vegetables, legumes, beans, olive oil and nuts but reduce meat consumption. | |
| Protein restriction | Reduction of dietary protein intake without changing the average caloric intake. | |
| Amino acid intervention | Specific restriction or supplement of amino acids including serine, glycine, tryptophan, histidine, lysine, methionine, threonine and branched-chain amino acid (leucine, isoleucine and valine). | |
| Micronutrient intervention | Applicable intervention of vitamins and minerals supplement such as low-salt diet. | |
| Metabolite intervention | Reduction or inhibiting biosynthesis of specific reaction intermediates or end-products of physiological metabolism, including N-acylethanolamines, folate metabolism intermediates, tricarboxylic cycle intermediates and coenzyme Q. | |
The mechanisms and effectors of dietary interventions
| Dietary intervention | Pathway | Species | Effect | Reference |
|---|---|---|---|---|
| Fasting | – | Human | ↓ fat mass, ↓ cholesterol, ↑ fatty acids, ↑ β-hydroxybutyrate | Stekovic et al.[ |
| TORC1 | Fly | ↑ autophagy, ↓ cysteine, ↑ acetyl-coenzyme A metabolism | Jouandin et al.[ | |
| Oxidative stress resistance | Yeast | ↑ lifespan | Brandhorst et al.[ | |
| RHEB-1, IGF, DAF-16 | Worm | ↑ lifespan | Honjoh et al.[ | |
| TOR independent | Fly | ↑ improved gut health | Catterson et al.[ | |
| IGF-1, PKA | Mouse | ↑ lifespan, ↑ rejuvenated immune system, ↓ visceral fat, ↓ cancer incidence, ↓ skin lesions, ↓ bone mineral density loss | Brandhorst et al.[ | |
| SIRT5 | Mouse | ↑ NAD+ level in liver, ↑ amino acid catabolism | Nakagawa et al.[ | |
| – | Human | ↑ fatty acids and β-hydroxybutyrate | Stekovic et al.[ | |
| Circadian regulation and autophagy | Fly | ↑ lifespan | Ulgherait et al.[ | |
| MON-2 | Worm | ↑ autophagy, ↑ lifespan | Jung et al.[ | |
| – | Human | ↑ insulin sensitivity, ↓ body mass and adiposity, ↓ inflammation, ↑ gut microbial diversity | Xie et al.[ | |
| BMAL1-PPARα | Mouse | ↓ body temperature, ↑ hepatic NADH level | Levine et al.[ | |
| p38-ATF7 | Worm | ↓ insulin/IGF-1, ↑ innate immunity, ↑ lifespan | Wu et al.[ | |
| – | Human | alteration of gut microbiome and immune cells, ↓ systolic blood pressure | Maifeld et al.[ | |
| – | Mouse | ↑ neurotrophiω-3, ↑ brain-derived neurotrophic factor | Lee et al.[ | |
| Caloric restriction | mTOR | Yeast | ↑ lifespan | Kaeberlein et al.[ |
| Worm | ↑ autophagy | Hansen et al.[ Kapahi et al.[ | ||
| Fly | ↓ protein synthesis, ↑ stress resistance, ↑ lifespan | Kapahi et al.[ | ||
| DAF-16/FOXO | Worm | ↑ lifespan | Greer et al.[ | |
| dFOXO independent | Fly | ↑ lifespan | Giannakou et al.[ | |
| FOXO1 | Mouse | ↓ inflammation, ↓ liver injury | Miyauchi et al.[ | |
| FOXO3, FOXO4 | Rat | ↓ age-associated muscles dysfunction | Furuyama et al.[ | |
| FOXO3 | Mouse | ↑ lifespan, ↓ cancer incidence | Shimokawa et al.[ | |
| SIRT1 | Worm | ↑ lifespan | Morselli et al.[ | |
| Rat | ↑ lifespan | Cohen et al.[ | ||
| Young non-obese human | ↑ muscle mitochondrial function | Civitarese et al.[ | ||
| SIRT3 | Mouse | ↑ NADPH, ↑ glutathione | Someya et al.[ | |
| Mouse | ↑ SOD2, ↓ ROS and oxidative stress | Qiu et al.[ | ||
| Mouse | ↓ mitochondrial protein acetylation | Hebert et al.[ | ||
| Mouse | ↑ mitochondrial glutathione antioxidant defense system | Someya et al.[ | ||
| SIR2, NPT1 | Yeast | ↑ lifespan | Lin et al.[ | |
| Worm | ↑ oxidative metabolism, ↑ lifespan | Moroz et al.[ | ||
| ER stress | Worm | ↑ ER-UPR, ↑ proteostasis, ↑ lifespan | Matai et al.[ | |
| AMPK | Worm | ↑ FAO, ↑ peroxisomal function ↑ mitochondrial network homoeostasis, ↑ lifespan | Weir et al.[ | |
| AKH | Fly | ↑ fatty-acid synthesis and breakdown, ↑ lifespan | Katewa et al.[ | |
| – | Mouse | ↓ FA intake, ↑ fatty-acid synthesis, ↑ FAO | Bruss et al.[ | |
| P38 | Worm | ↑ PUFAs, especially LA and EPA | Chamoli et al.[ | |
| PGC-1α | Mouse | ↑ mitochondrial biogenesis and function, ↓ ROS | López-Lluch et al.[ | |
| – | Mouse | ↓ oxidant emission, ↑ antioxidant scavenging, ↓ oxidative damage | Lanza et al.[ | |
| miR-144/Nrf2 | Rat | ↓ inflammation, ↑ cerebrovascular function | Csiszar et al.[ | |
| Tim | Fly | ↑ lifespan | Katewa et al.[ | |
| – | Mouse Human | ↓ inflammation, ↑ reversed the aging-disturbed immune ecosystem | Ma et al.[ | |
| PLA2G7 | Mouse Human | ↓ thymic lipoatrophy, ↓ inflammation, ↑ metabolic health | Spadaro et al.[ | |
| Bacterial lipid A synthetase | Mouse | ↓ inflammation and proinflammatory immune cells, ↓ fatty liver, ↑ beige fat | Fabbiano et al.[ | |
| Clostridioides difficile | Mouse Human | ↓ body weight, ↑ metabolic improvement | von Schwartzenberg et al.[ | |
| – | Human | ↑ alpha diversity of the gut microbiota, ↓ intestinal effector memory CD8+ T cells, ↓ intestinal memory B cells, ↓ hepatic effector memory CD4+, ↓ CD8+ T cells | Sbierski-Kind et al.[ | |
| – | Mouse | ↑ neurogenesis | Bondolfi et al.[ Weng et al.[ Lee et al.[ | |
| Ketogenic diet | – | Mouse | ↓ Th17 cells, ↓ bifidobacterial growth | Ang et al.[ |
| Hcar2 | Mouse Human | ↓ ISCs function, ↓ tumorigenesis | Dmitrieva-Posocco et al.[ | |
| H3K9, PGC-1α, FOXO1 | Mouse | ↑ pentose phosphate and glycogen, ↑ T-cell memory development | Zhang et al.[ | |
| hnRNP A1/Oct4 | Mouse | ↓ senescent cells | Han et al.[ | |
| – | Mouse | ↓ senescent cells | Roberts et al.[ | |
| PUFA-rich diet | – | Mouse | ↓ effector memory CD4+ T cells | Cucchi et al.[ |
| Glucose and carbohydrate restriction | AMPK | Worm | ↑ ROS, ↑ oxidative stress resistance response | Schulz et al.[ |
| NHR-49/CBP | Worm with Huntington's disease | ↓ proteotoxicity, ↑ lifespan | Marcellino et al.[ | |
| High-fibre diet/short-chain fatty acids (SCFAs) supplements | FFAR2, FFAR3 | Mouse | ↑ SCFAs levels, ↑ ILCs proliferation | Sepahi et al.[ |
| – | Mouse | ↑ microbial CAZymes activity | Wastyk et al.[ | |
| Fermented/ probiotic diet | – | Mouse | ↑ alpha diversity of the gut microbiota, ↓ inflammation | Wastyk et al.[ |
| Protein restriction | TOR | Worm | ↓ protein synthesis | Bonawitz et al.[ |
| TOR | Fly | ↑ lifespan | Jensen et al.[ | |
| – | Fly | ↑ lifespan | Lee et al.[ Stefana et al.[ Fanson et al.[ | |
| mTORC1 | Mouse | ↓ BCAA and glucose metabolism | Solon-Biet et al.[ | |
| GCN2-ATF4 | ↑ FGF21, ↑ food intake, ↑ energy expenditure, ↓ body fat weight, ↑ body lean weight | Laeger et al.[ | ||
Asparagine+ glutamate restriction | MSN2/4 | Yeast | ↑ lifespan | Powers et al.[ |
| BCAA restriction | mTOR | Mouse | ↑ lifespan in males, ↓ frailty | Yu et al.[ |
| Cystine restriction | GCN2/ATF4/SESN2/mTOR | Mouse Human | ↓ tumour growth, ↑ efficiency of chemotherapy | Wu et al.[ |
| Methionine restriction | TOR | Yeast | ↑ lifespan | Lee et al.[ |
| – | Yeast | ↑ autophagy, ↑ lifespan | Ruckenstuhl et al.[ | |
| – | Mouse | ↓ senescent cells | Parkhitko et al.[ | |
| – | Yeast | ↑ lifespan | Sutter et al.[ | |
| Sestrin | Fly | ↑ lifespan, ↑ regulation of ISCs and gut health, ↓ age-related gut pathology | Lu et al.[ | |
| GH | Mouse | ↑ lifespan | Brown-Borg et al.[ | |
| – | Mouse | ↑ macrophage migration inhibition factor in liver, ↓ insulin/ IGF-1, ↓ glucose, ↓ thyroid hormone | Miller et al.[ | |
| – | Rat | ↑ lifespan | Zimmerman et al.[ | |
| – | Rat | ↑ lifespan, ↓ mitochondrial ROS, ↓ oxidative damage | Sanz et al.[ | |
| K restriction | Vacuolar acidity | Yeast | ↑ lifespan | Sasikumar et al.[ |
| Fe restriction | Proteostasis | Worm | ↑ lifespan | Klang et al.[ |
| Zn restriction | DAF-16 | Worm | ↑ lifespan | Kumar et al.[ |
| Zn supplement | BMP4/GPR39 | Mice | ↑ T cell development | Iovino et al.[ |
| Se supplement | GPX4 | Mouse Human | ↑ follicular helper T cells, ↑ antibody responses for influenza vaccination | Yao et al.[ |
| High-salt diet | – | Mouse | ↑ anti-tumour function of NK cells, ↓ tumour growth | Rizvi et al.[ |
| Metabolite intervention | ||||
| NR supplement | – | Overweight or obese female | ↑ muscle insulin sensitivity | Yoshino et al.[ |
| Clock repressor PER2 | Old mouse | ↑ NAD+ level, ↓ aging | Levine et al.[ | |
| cGAS-STING | APP/PS1 mutant mouse | ↑ NAD+ level in brain, ↓ inflammatory cytokines, ↑ cognitive and synaptic function | Hou et al.[ | |
| Spermidine supplement | eIF5A | Mouse | ↑ memory B-cell response | Zhang et al.[ |
AKH adipokinetic hormone, AMPK AMP-activated protein kinase, ATF4 activating transcription factor 4, ATF7 activating transcription factor 7, BCAA branched-chain amino acids, BMAL1 brain and muscle Arnt-like protein 1, BMP4 bone morphogenetic protein 4, CBP CREB-binding protein, cGAS cyclic GMP-AMP synthase, DAF-16 abnormal dauer formation 16 (FOXO ortholog), eIF5A eukaryotic initiation factor 5A, EPA eicosapentaenoic acid, ER endoplasmic reticulum, FA fatty acid, FAO fatty acid oxidation, FFAR2 free fatty acid receptor 2, FFAR3 free fatty acid receptor 3, FGF21 fibroblast growth factor 21, FOXO1 forkhead box O1, FOXO3 forkhead box O3, FOXO4 forkhead box O4, GCN2 general control nonderepressible 2, GH growth hormone, GPR39 G-protein coupled receptor 39, GPX4 glutathione peroxidase 4, GSH glutathione. H3K9 histone H3 lysine 9, hnRNP A1 heterogeneous nuclear ribonucleoprotein A1, IGF-1 insulin-like growth factor 1, ILCs innate lymphoid cells, ISCs intestinal stem cells, LA linoleic acid, miR-144 microRNA 144, MSN2/4 multiple suppressor of SNF1 mutation 2/4, mTOR mammalian target of rapamycin, NAD nicotinamide adenine dinucleotide, NADPH nicotinamide adenine dinucleotide phosphate, NHR-49 nuclear hormone receptor-49, NPT1 nicotinate phosphoribosyltransferase 1, NR nicotinamide riboside, Nrf2 nuclear factor E2-related factor 2, Oct4 Octamer-binding transcriptional factor 4, PER2 Period2, PGC-1α peroxisome proliferation-activated receptor coactivator 1 α, PKA protein kinase A, PLA2G7 platelet activating factor acetyl hydrolase, PPARα peroxisome proliferator-activated receptor-α, PUFAs polyunsaturated fatty acids, RHEB-1 Ras homologue enriched in brain (RHEB ortholog), ROS reactive oxygen species, SCFAs short-chain fatty acids, SESN2 sestrin 2, SIR2 silent information regulator 2 (SIRT1 ortholog), SIRT1 sirtuin 1, SIRT3 sirtuin 3, SIRT5 sirtuin 5, SOD2 superoxide dismutase 2, STING stimulator of interferon genes, Tim Timeless, TOR target of rapamycin (mTOR ortholog), TORC1 target of rapamycin complex 1, UPR unfolded protein response.
Fig. 2Molecular and effector mechanisms of dietary intervention. Dietary intervention engages by alterable consumption of numerous nutrients, including carbohydrates, lipids, amino acids, micronutrients, and metabolites. Nutrient signals under diverse dietary interventions lead to activation of multiple biochemical pathways. As a result, these pathways involve in downstream effectors like cytokines secretion, immunoregulation, gut microbiome homoeostasis, elimination of senescent cells, and neuromodulation
Fig. 3Functionality of dietary interventions on human tissues under health and diverse disease states. Dietary interventions exert beneficial effects across varying aspects, including nervous system, cardiovascular system, respiratory system, metabolic system, renal system, endocrine system, and digestive system as well as cancer
The roles of dietary interventions in disease models
| Disease | Regimen | Model | Effect | Reference |
|---|---|---|---|---|
| Metabolic syndrome | CR | Mouse | ↑ M2 macrophage, ↑ eosinophils, ↑ fat beige | Fabbiano et al.[ |
| old mouse | ↑ adiponectin | Miller et al.[ | ||
| db/db mouse | ↑ insulin sensitivity, ↑ β cell mass, ↑ utilization of fatty acids, ↓ apoptosis, ↓ oxidative stress, ↓ myocardial inflammation, ↓ fibrosis, ↓ inflammation | Cohen et al.[ Kanda et al.[ Waldman et al.[ | ||
| DIO mouse | ↑ VEGF, ↑ M2 macrophage | Kim et al.[ | ||
| CR and IF | Mouse | ↓ hyperglycaemia and diacylglycerol in liver | Baumeier et al.[ | |
| APF/FMD | Middle-aged mouse Old mouse Human | ↓ visceral fat, ↓ IGF-1 levels and PKA activity, ↓ Glucose, ↓ body weight, ↓ CRP, ↑ Ketone body, ↑ IGFBP-1, ↑ MSPC | Brandhorst et al.[ Pak et al.[ | |
| PR | Mouse | ↓ hyperglycaemia, ↓ β cell loss | Laeger et al.[ | |
| MR | Mouse | ↑ insulin sensitivity, ↑ energy expenditure | Castano-Martinez et al.[ | |
| BR | DIO mouse | ↑ WAT browning, ↓ adiposity | Ma et al.[ | |
| FRD | DIO mouse | ↑ levels of branched-chain hydroxy acids, ↑ insulin sensitivity, ↓ hyperglycaemia | Daniel et al.[ | |
| Cardiovascular diseases | CR | ob/ob mouse | ↑ leptin in heart | Sloan et al.[ |
ob/ob mouse db/db mouse | ↓ oxidative stress, ↓ fibrosis, ↓ inflammation, ↓ myocyte hypertrophy | An et al.[ | ||
| PF | DIO mouse | ↑ cardiac vascularity and function | Mishra et al.[ | |
| IF | Rat | ↓ hypertension pathogenesis | Shi et al.[ | |
| FRD | Hypertensive mouse | ↑ SCFAs, ↑ circadian rhythm, ↓ cardiac hypertrophy, ↓ fibrosis, ↓ blood pressure | Marques et al.[ | |
| KD | Mouse | ↑ proliferation of cardiac endothelial cells, ↓ heart hypertrophy | Weis et al.[ | |
| Intestinal malfunction | CR | Fly Worm | ↑ intestinal barrier function, ↑ autophagy, ↑ IRE1/XBP1 | Akagi et al.[ Luis et al.[ Gelino et al.[ |
| Mouse | ↑ balanced immunoregulation | Shibolet et al.[ | ||
| KD | Mouse | ↓ inflammation, ↓ ILC3s | Kong et al.[ | |
| MR | Mouse | ↑ ROS response, ↓ inflammation | Liu et al.[ | |
| SR | Mouse | ↓ inflammation | Kitamoto et al.[ | |
| Renal diseases | CR and PR | Mouse | ↓ injury post-reperfusion | Robertson et al.[ |
| CR and STF | Mouse | ↑ renal function, ↓ injury post-reperfusion, ↓ inflammation | Shushimita et al.[ | |
| PR | Mouse | ↓ renal ammonia excretion | Lee et al.[ | |
| KD | DKD mouse | ↑ diabetic albuminuria, ↑ glomerulopathy, ↓ podocyte injury, ↓ senescence | Fang et al.[ | |
| FRD | Mouse | ↓ renal fibrosis | Marques et al.[ | |
| EPA supplement | Mouse | ↑ autophagy, ↑ renal ischaemia reperfusion | Yamamot et al.[ | |
| Nervous system diseases | CR | Mouse Monkey | ↑ neurological function | Gräff et al.[ Bendlin et al.[ |
| Mouse | ↑ neurotrophic factors, ↓ stress response | Vermeij et al[ Duan et al.[ | ||
| Obese mouse | ↓ neuronal cell death | Shruthi et al.[ | ||
| PD mouse | ↓ inflammation, ↓ oxidative stress, ↑ remodelled gut microbiota, ↑ protect the substantia nigra and dopaminergic neurons | Zhou et al.[ | ||
| AD mouse | ↑ blood–brain barrier, ↑ cognitive function | Bredesen et al.[ Tomi et al.[ | ||
| HD mouse | ↓ striatal human HTT expression, ↓ histone acetylation modifications | Moreno et al.[ | ||
| CR and KD | Old mouse | ↑ memory | Newman et al.[ Rojic-Becker et al.[ | |
| APF/FMD | middle-aged mouse Old mouse Human | ↑ hippocampal neurogenesis, ↑ NeuroD1, ↑ cognitive performance | Sebastian et al.[ | |
| Spermidine supplement | Fly | ↑ memory and locomotion loss, ↓ senescent mitochondria | Liang et al.[ | |
| FRD | Mouse | ↑ microglial maturation defects, ↑ synaptic impairments | Liu et al.[ | |
| TRF | HD mouse | ↑ motor function, ↑ circadian rhythms | Wang et al. | |
| IF | MS mouse MS human | ↓ IL-17 producing T cells, ↑ Treg in gut | Francesca et al.[ | |
| Rat | ↑ short-term and spatial memory | Shin et al.[ | ||
| Mouse | ↓ neuronal hyperexcitability, ↓ hippocampal synaptic plasticity deficits | Liu et al.[ | ||
| Mouse | ↑ brain inflammation, ↑ neuronal injury | Lazic et al.[ | ||
| Muscle and skeletal diseases | CR | Monkey | ↑ muscle structure | Mattison et al.[ |
| Mouse | ↑ mitochondrial function, ↑ autophagy | Gutiérrez-Casado et al.[ | ||
| Rat | ↓ muscular apoptosis | Marzetti et al.[ | ||
| Mouse | ↓ oxidative stress | Jang et al.[ | ||
| Mouse | ↑ optimize the proteasome-dependent degradation | Hepple et al.[ | ||
| Sarcopenia mouse Sarcopenia monkey | ↑ muscle mass | van Norren et al.[ McKiernan et al.[ | ||
| Mouse | ↑ muscle integrity | Ham et al.[ | ||
| Rat | ↑ bone weakening, ↑ osteoporosis, ↑ bone-healing ability | Villareal et al.[ Bodnar et al.[ | ||
| BCAA supplement | Mouse Human | ↑ skeletal muscle hypertrophy | Aoyama et al.[ | |
| αKG supplement | Old mouse | ↑ osteogenesis, ↑ bone regeneration | Wang et al.[ | |
| APF/FMD | Middle-aged mouse Old mouse Human | ↓ bone mineral density | Sebastian et al.[ | |
| Endocrine system diseases | CR | Rat | ↓ growth-associated hormones | Trivedi et al.[ |
| Rat | ↑ glucocorticoid | Qiu et al.[ | ||
| Respiratory system diseases | CR | Mouse | ↑ prevents pulmonary MTB infection | Palma et al.[ |
| KD | Mouse | ↑ γδ T cells expansion, ↑ lung barrier functions to resist influenza virus infection | Goldberg et al.[ | |
| Tryptophan supplement | Mouse | ↑ sensitivity to anti-MTB therapy | Puyskens et al.[ | |
| FRD | Mouse | ↑ fibre-fermenting bacteria, ↑ SCFAs, ↓ allergic inflammation | Trompette et al.[ | |
| Mouse | ↑ survival of influenza-infected mice, ↑ functionality of CD8+ effector T cells | Trompette et al.[ | ||
| Cancer | CR | Mouse | no benefit in delaying growth or progression of neuroendocrine tumours | Sharp et al.[ |
| Mouse | ↓ tumours | Shimokawa et al.[ | ||
| DIO mouse | ↓ proinflammatory cytokines, ↓ angiogenic factors, ↓ tumour metastasis | Sundaram et al.[ | ||
| Mouse | ↑ survival, ↓ metastasis, ↓ IGF-1R, ↓ inflammatory cytokines | Simone et al.[ | ||
| Mouse | ↑ p53, ↓ tumorous growth | Ma et al.[ | ||
| SRF | Mouse | ↓ IGF-1, ↑ ratio of CD8+ T/Treg, ↑ efficacy of immunotherapy | Ajona et al.[ | |
| Mouse | ↓ IGF-1, ↓ Treg, ↑ efficacy of chemotherapy | Pietrocola et al.[ | ||
| Mouse | ↑ efficacy of sorafenib | Krstic et al.[ | ||
| TRF | DIO mouse | ↓ tumour initiation, ↓ obesity-promoted malignant growth, ↓ pulmonary metastasis focuses | Das et al.[ | |
| αKG supplement | Mouse | ↑ p53, ↓ tumorous growth | Morris et al.[ | |
| KD | Mouse | ↑ acetoacetate, ↑ growth in mice inoculated with BRAFV600E-mutant melanoma cells | Xia et al.[ | |
| Mouse | ↑ balanceable proportion of saturated/unsaturated fatty acids, ↓ tumorous stearoyl-CoA desaturase activity, ↓ malignant growth | Lien et al.[ | ||
| Mouse | ↑ efficacy of chemotherapy | Yang et al.[ | ||
| Mouse | ↑ efficacy of immune checkpoint inhibitors | Ferrere et al.[ | ||
Mouse Human | ↓ ISCs function, ↓ tumorigenesis | Dmitrieva-Posocco et al.[ | ||
| PUFA supplement | Mouse | ↑ ferroptosis, ↓ tumour growth | Dierge et al.[ | |
| PR | Mouse | ↓ tumour growth | Fontana et al.[ | |
| Mouse | ↑ response to immunotherapies, ↑ proinflammatory phenotypes, ↓ tumour growth | Orillion et al.[ | ||
| Mouse | ↑APCs and CD8+ T cells, ↓ tumour growth | Rubio-Patino et al.[ | ||
| SR | Mouse | ↓ proliferation of T cells, ↓ tumour growth | Ma et al.[ Maddocks et al.[ Sullivan et al.[ | |
| MR | Mouse Human | ↓ metastasis, ↑ efficacy of chemotherapy ↑ disease-free survival | Gao et al.[ Golbourn et al.[ | |
| Cystine restriction | Mouse Human | ↓ tumour growth, ↑ efficacy of chemotherapy | Wu et al.[ | |
| AR | Mouse | ↓ ASS1-deficient tumour growth | Poillet-Perez et al.[ | |
| Arginine supplementation | Mouse | ↓ tumorigenesis ↑ generation of central memory T cells, ↑ survival of T cells | Geiger et al.[ | |
| BR | Mouse Human | ↓ tumorigenesis, ↓ tumour growth | Li et al.[ Thandapani et al.[ | |
| Se supplement | Mouse | ↑ anticancer properties | Wawrzyniak et al.[ | |
| Zn supplement | Mouse | ↑ DNA repair function | ||
| Mg supplement | Mouse | ↑ coenzyme function for DNA polymerases | ||
| FMD | Mouse | ↑ efficacy of endocrinotherapy | Caffa et al.[ | |
| FRD | Human Mouse | ↑ progression-free survival, ↑ efficacy of anti-PD-1-based therapy | Spencer et al.[ | |
| Mouse | ↑ efficacy of CAR-T cells | Luu et al.[ | ||
| Mouse | ↓ efficacy of CTLA-4 blockade | Coutzac et al.[ | ||
| NR supplement | Mouse | ↑ cell-killing function of CTLs | Wang et al.[ | |
| Mouse | ↑ efficacy of PD-L1 blockade | Lv et al.[ | ||
| K+ supplement | Mouse | ↑ efficacy of CAR-T cells | Vodnala al.[ |
αKG α ketoglutarate, AD Alzheimer’s disease, ADF alternate-day fasting, ALL acute lymphocytic leukaemia, ALP alkaline phosphatase, APCs antigen-presenting cells, APF alternating prolonged fasting, AR arginine restriction, ASS1 argininosuccinate synthase 1, BCAA branched-chain amino acid, BR branched-chain amino acid restriction, CR caloric restriction, CRP C-reactive protein, CTL cytotoxic T lymphocyte, DIO diet-induced obesity, DKD diabetic kidney disease, EPA eicosapentaenoic acid, EV-D68 Enterovirus D68, FCR fermentable carbohydrate restriction, FMD fasting-mimicking diet, FRD fibre-rich diet, GGT gamma-glutamyl transferase, HD Huntington’s disease, IF intermittent fasting, IGF-1 insulin-like growth factor 1, IGF-1R insulin-like growth factor-1 receptor, IGFBP-1 insulin-like growth factor binding protein-1, IL-17 interleukin-17, ILC3s innate lymphoid cells group 3, IRE1 inositol-requiring enzyme 1, ISCs intestinal stem cells, KD ketogenic diet, MCT medium-chain triglycerides, MD Mediterranean diet, MR methionine restriction, MS multiple sclerosis, MSPC mesenchymal stem/progenitor cells, MTB pulmonary mycobacterium tuberculosis, NR nicotinamide riboside, PD Parkinson's disease, PF periodic fasting, PKA protein kinase A, PR protein restriction, PUFA polyunsaturated fatty acid, SCFAs short-chain fatty acid, SR serine restriction, STF short-term fasting, Treg regulatory T cell, TRF time-restricted feeding, VEGF vascular endothelial growth factor, WAT white adipose tissue, XBP1 X-box binding protein 1.
The clinical trials of dietary interventions in disease
| Disease | Regimen | Effect | Registration number | Reference |
|---|---|---|---|---|
| Metabolic syndrome | CR | ↓ body weight, ↓ reactive oxygen species | NCT00427193 NCT02695511 | Redman et al.[ |
| ↓ ALP, ↓ GGT, ↑ bilirubin | NCT00427193 | Dorling et al.[ | ||
| ↓ body weight, ↓ body fat, ↓ blood pressure | NCT03745612 | Liu et al.[ | ||
| IF | ↓ body weight, ↑ insulin sensitivity, ↑ Akkermansiaceae, ↑ Christensenellaceae, ↑ Tanerellaceae | NCT02449148 | Sowah et al.[ | |
| TRF | ↓ oxidative stress, ↓ insulin resistance, ↓ body weight | NCT03867773 | Cienfuegos et al.[ | |
| ↑ cardiometabolic health | NCT03182985 | Wilkinson et al.[ | ||
| Plant-rich diet | alter plasma metabolites, ↓ diabetes risk | Nurses’ Health Study, Nurses’ Health Study II and Health Professionals Follow-up Study | Wang et al.[ | |
| MD | ↓ cholesterol, ↑ insulin sensitivity, ↓ inflammation, ↑ Faecalibacterium prausnitzii | NCT03071718 | Meslier et al.[ | |
| FRD | ↑ insulin sensitivity | NCT03477916 | Mocanu et al.[ | |
| FRD and excise | ↓ body weight, ↓ cholesterol level in plasma and liver, ↑ glucose tolerance | NCT03852069 | Rodriguez et al.[ | |
| Cardiovascular diseases | CR | ↓ heart rate and blood pressure | NCT00427193 NCT02695511 | Redman et al.[ |
| PF | ↓ blood pressure | NCT02099968 | Maifeld et al.[ | |
| MD | microbial changes, ↓ body weight, ↓ cardiometabolic biomarkers | NCT03020186 | Rinott et al.[ | |
| ↓ atherosclerosis, ↓ cardiovascular events | NCT00924937 | Delgado-Lista et al.[ Jimenez-Torres et al.[ | ||
| alter functional and components of the gut microbiome | Health Professionals Follow-up Study | Wang et al.[ | ||
| Intestinal malfunction | FRD | ↓ inflammation | NCT04147598 | Fritsch et al.[ |
| FCR | ↑ functional gastrointestinal symptoms | U.K. tertiary IBD center | Prince et al.[ | |
| Renal diseases | AGEs restriction | ↑ balance gut microbiota | NCT02467530 | Yacoub et al.[ |
| MD | ↑ kidney function | NCT00924937 | Podadera-Herreros et al.[ | |
| Nervous system diseases | MCT supplement | ↑ cognitive and gait functions | UMIN000033447 | Mutoh al.[ |
| NR | ↓ inflammation | NCT03816020 | Brakedal et al.[ | |
| MD | ↑ cognitive function, ↓ inflammation, microbiome alterations | NCT01754012 | Ghosh et al.[ | |
| IF | ↓ IL-17 producing T cells, ↑ Treg in gut | NCT02411838 | Cignarella et al.[ | |
| Endocrine system diseases | CR | ↓ energy expenditure, ↓ thyroid axis activity | NCT00427193 NCT02695511 | Redman et al.[ |
| ↓ mammary-gland and ovulation | IRCT20140907019082N9 | Tabrizi et al.[ | ||
| ↑ testosterone | – | Schulte et al.[ | ||
| ADF | ↓ circulating fT3, ↑ parathyroid hormone | NCT02673515 | Stekovic et al.[ | |
| Respiratory system diseases | CR | ↑ improve dyspnoea and obstruction symptoms | ACTRN126000056897 | McDonald et al.[ |
| KD | ↑ respiratory function | – | Rubini et al.[ | |
| Cancer | KD-IF | ↓ leptin and insulin, ↑ uric acid | NCT01754350 | Voss et al.[ |
| Asparaginase supplement | agent in chemotherapy of ALL | NCT03987542 | Gottschalk et al.[ | |
| FMD | ↓ Treg and immunosuppressive myeloid, ↑ CD8+ T cell, ↑ response to immunotherapies | NCT03340935 | Vernieri et al.[ | |
| ↑ efficacy of neoadjuvant chemotherapy | NCT02126449 | de Groot et al.[ | ||
| FRD | ↓ risk of lung cancer | – | Yang et al.[ | |
| Prebiotics supplementation | ↑ efficacy of immune checkpoint inhibitors | NCT03829111 | Dizman et al.[ |
ADF alternate-day fasting, AGEs advanced glycation end products, ALL acute lymphocytic leukaemia, ALP alkaline phosphatase, CR caloric restriction, FCR fermentable carbohydrate restriction, FMD fasting-mimicking diet, FRD fibre-rich diet, GGT gamma-glutamyl transferase, IF intermittent fasting, IL-17 interleukin-17, KD ketogenic diet, MCT medium-chain triglycerides, MD Mediterranean diet, NR nicotinamide riboside, PF periodic fasting, Treg regulatory T cell, TRF time-restricted feeding.